hypertrophic cardiomyopathy
Conditions
Interventions
Gold Standard:Clinical outcome
Index test:18FAl-NOTA-FAPI 
imaging 
quantitatively 
fibrosis
Sponsors
Beijing Chaoyang Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
14 Years to No maximum
Inclusion criteria
Inclusion criteria: 1.Patients 14 years and older with clinically confirmed HCM, i.e., 2-d echocardiography or cardiac magnetic resonance imaging showing maximum end-diastolic thickness in any part of the left ventricle >=15 mm, and no other cause of myocardial hypertrophy; 2.Patients with 13-14 mm myocardial hypertrophy had positive gene test or family members with HCM; 3.The increase of left ventricular wall thickness was more than the average value plus 2 standard deviations (or Z value > 2) in children of the same age, sex and body surface area.
Exclusion criteria
Exclusion criteria: 1.Patients received invasive treatment, including percutaneous ventricular septal myocardial ablation, surgical ventricular septal myocardial resection, permanent pacemaker implantation ( ICD ), etc.; 2.Patients with other cardiac or systemic diseases that can cause myocardial hypertrophy, such as aortic stenosis and amyloidosis; 3.History of coronary heart disease, myocardial infarction, related examination also suggested coronary heart disease and myocardial infarction; 4.Patients with valve heart disease and other cardiomyopathy; 5.Relevant examinations indicate systemic inflammation or infectious diseases; 6.Patients with malignant tumor; 7.Other systemic diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| standardized uptake ratio; | — |
Countries
China
Contacts
Public ContactYang Minfu
Beijing Chaoyang Hospital, Capital Medical University
Outcome results
None listed